Evidence map›Paper›PMID 35428762›Full record

ArticleCell death & disease2022

The nuclear receptor REV-ERBα is implicated in the alteration of β-cell autophagy and survival under diabetogenic conditions.

Matthew R Brown, Damien Laouteouet, Morgane Delobel, Orianne Villard, Christophe Broca, Gyslaine Bertrand, Anne Wojtusciszyn, Stéphane Dalle, Magalie A Ravier, Aleksey V Matveyenko and 1 more

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Matthew R BrownDepartment of Physiology and Biomedical Engineering, Mayo Clinic School of Medicine, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0001-7429-2657
Damien LaouteouetInstitute of Functional Genomics, University of Montpellier, CNRS, INSERM, Montpellier, France.
Morgane DelobelInstitute of Functional Genomics, University of Montpellier, CNRS, INSERM, Montpellier, France.
Orianne VillardLaboratory of Cell Therapy for Diabetes (LTCD), PRIMS facility, Institute for Regenerative Medicine and Biotherapy (IRMB), University hospital of Montpellier, Montpellier, France.
Christophe BrocaLaboratory of Cell Therapy for Diabetes (LTCD), PRIMS facility, Institute for Regenerative Medicine and Biotherapy (IRMB), University hospital of Montpellier, Montpellier, France.
Gyslaine BertrandInstitute of Functional Genomics, University of Montpellier, CNRS, INSERM, Montpellier, France.
Anne WojtusciszynInstitute of Functional Genomics, University of Montpellier, CNRS, INSERM, Montpellier, France.
Stéphane DalleInstitute of Functional Genomics, University of Montpellier, CNRS, INSERM, Montpellier, France.
Magalie A RavierInstitute of Functional Genomics, University of Montpellier, CNRS, INSERM, Montpellier, France.ORCID 0000-0001-6607-6559
Aleksey V MatveyenkoDepartment of Physiology and Biomedical Engineering, Mayo Clinic School of Medicine, Mayo Clinic, Rochester, MN, USA. Matveyenko.Aleksey@mayo.edu.ORCID 0000-0001-7761-4842
Safia CostesInstitute of Functional Genomics, University of Montpellier, CNRS, INSERM, Montpellier, France. safia.costes@igf.cnrs.fr.ORCID 0000-0001-8323-1207
Centre National de la Recherche Scientifique · FRCentre Hospitalier Universitaire de Montpellier · FRMayo Clinic · US

Funding

Role of Circadian Misalignment in Beta-cell Failure in Type 2 DiabetesR01DK098468 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ALEKSEY V MATVEYENKO · 2013 to 2026
$5.8M
NBCe1-mediated Regulation of HCO3- is a Novel Mechanism Underlying Metabolic Reprogramming and CystogenesisK00DK123834 · NIDDK · BROAD INSTITUTE, INC. · PI BROWN, MATTHEW · 2022 to 2025
$369k
NBCe1-mediated Regulation of HCO3- is a Novel Mechanism Underlying Metabolic Reprogramming and CystogenesisF99DK123834 · NIDDK · MAYO CLINIC ROCHESTER · PI BROWN, MATTHEW · 2019 to 2020
$92k
NIDDK NIH HHS F99 DK123834NIDDK NIH HHS K00 DK123834NIDDK NIH HHS R01 DK098468
6 · The paper itself

Abstract

Pancreatic β-cell failure in type 2 diabetes mellitus (T2DM) is associated with impaired regulation of autophagy which controls β-cell development, function, and survival through clearance of misfolded proteins and damaged organelles. However, the mechanisms responsible for defective autophagy in T2DM β-cells remain unknown. Since recent studies identified circadian clock transcriptional repressor REV-ERBα as a novel regulator of autophagy in cancer, in this study we set out to test whether REV-ERBα-mediated inhibition of autophagy contributes to the β-cell failure in T2DM. Our study provides evidence that common diabetogenic stressors (e.g., glucotoxicity and cytokine-mediated inflammation) augment β-cell REV-ERBα expression and impair β-cell autophagy and survival. Notably, pharmacological activation of REV-ERBα was shown to phenocopy effects of diabetogenic stressors on the β-cell through inhibition of autophagic flux, survival, and insulin secretion. In contrast, negative modulation of REV-ERBα was shown to provide partial protection from inflammation and glucotoxicity-induced β-cell failure. Finally, using bioinformatic approaches, we provide further supporting evidence for augmented REV-ERBα activity in T2DM human islets associated with impaired transcriptional regulation of autophagy and protein degradation pathways. In conclusion, our study reveals a previously unexplored causative relationship between REV-ERBα expression, inhibition of autophagy, and β-cell failure in T2DM.

Indexed as

Circadian ClocksDiabetes Mellitus, Type 2AutophagyCircadian RhythmHumansInflammationNuclear Receptor Subfamily 1, Group D, Member 1Nuclear Receptor Subfamily 1, Group D, Member 1

Identifiers

PMID35428762
PMCPMC9012816
OpenAlexW4223991538

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.